Rodin Therapeutics, Inc., a Cambridge MA-based biotechnology company applying insights of epigenetics to novel therapeutics for neurological disorders, closed a $12.9M Series A financing round.
The round was led by current investors Atlas Venture and Johnson & Johnson Development Corporation (JJDC).
The company, co-founded in March 2013 by Atlas Venture and Proteros Biostructures, with financing from the Johnson & Johnson Development Corporation (JJDC), intends to use the funds to advance its pipeline of selective epigenetic modulators towards the clinic.
Led by Bruce Booth, Chairman and acting CEO, and a Partner at Atlas Venture, Marty Jefson, Chief Scientific Officer, Ankit Mahadevia, Acting Chief Business Officer and Venture Partner at Atlas Venture, and Bruce Booth, Rodin Therapeutics is discovering and developing therapeutics for cognitive disorders, applying insights into the role of epigenetics and structural biology capabilities.
The company has advanced its internal pipeline of epigenetic modulators and obtained an exclusive license to an additional chemical series developed at the Broad Institute and tested at Rodin.